Drugs / IMC-EB10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00887926 | Jun 2009 → Aug 2010 | myeloid leukemia | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-EB10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00887926 ↗ |
| Modality | Monoclonal antibody | “the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal antibody IMC-EB10” NCT00887926 ↗ |
| Route | Intravenous | “All participants will receive intravenous infusions of IMC-EB10” NCT00887926 ↗ |
| Target | FLT3 | “the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal antibody IMC-EB10” NCT00887926 ↗ |